Form 4: Alkermes Executive Blair C. Jackson Reports Stock Transactions

EVP and Chief Operating Officer of Alkermes plc, Blair Curtis Jackson, reports transactions involving ordinary shares and restricted stock units.

Summary

• Blair Curtis Jackson, EVP and Chief Operating Officer of Alkermes plc, filed a Form 4 detailing changes in beneficial ownership.
• On February 22, 2025, Jackson exercised restricted stock units to acquire 9,694 ordinary shares and disposed of 4,305 shares to cover tax obligations at a price of $35.32.
• Following these transactions, Jackson directly owns 191,883 ordinary shares.
• On February 23, 2025, Jackson exercised restricted stock units to acquire 8,738 ordinary shares and disposed of 3,880 shares to cover tax obligations at a price of $35.32.
• Following these transactions, Jackson directly owns 196,741 ordinary shares.
• Jackson also holds 17,476 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry where equity compensation is prevalent.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, particularly in the pharmaceutical and biotechnology sectors.
• Companies like Amgen, Biogen, and Gilead Sciences also regularly report similar Form 4 filings for their executives.
• The vesting schedules and equity compensation plans are often benchmarked against industry standards to attract and retain talent.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely negligible.

Key Dates